Biotech accelerator eyes $100M fund; Novartis, Enanta launch hep C combo study;

@FierceBiotech: Daiichi Sankyo bets up to $650M on Charleston's pain potential. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: Interesting fact, when DoD stopped $SRPT's work on Ebola, they left in a provision to reactivate the $291M contract. Article | Follow @JohnCFierce

@DamianFierce: RT @FierceBiotech: New special report: The top 15 late-stage blockbusters in the pipeline. Feature | Follow @DamianFierce

> Biotech accelerator BioMotiv has raised $50 million of a planned $100 million fund, according to a filing. More

> Novartis ($NVS) has launched a Phase I hepatitis C study using partner Enanta Pharmaceuticals' ($ENTA) EDP-239 in tandem with its own alisporivir. News

> Theravance ($THRX) has picked a CEO to lead after it splits in two, appointing Chief Financial Officer Michael Aguiar to take the reins Aug. 15. Current CEO Rick Winningham will run the company's spinout, Theravance Biopharma. Item

Medical Device News

@FierceMedDev: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. FierceDrugDelivery story | Follow @FierceMedDev

@StacyALawrence: Ten big med tech companies add 25,000 jobs in 2013. Article | Follow @StacyALawrence

@VarunSaxena2: Stentys ditches bare metal stents as customers move to drug-eluting versions. ICYMI from FierceDrugDelivery | Follow @VarunSaxena2

@MichaelGFierce: Thin and strong, graphene sheets form spheres spontaneously for drug release. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Saving Lives at Birth initiative developing innovative devices to improve infant health in underserved communities. More from National Geographic | Follow @EmilyWFierce

> St. Jude Medical seals the deal on NeuroTherm to gain ground in neuromodulation. News

> NeuroPace RNS Stimulator secures add-on payments from CMS. Story

> Alere to complete strategic review by year-end. Article

Pharma News

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Subscribe here, if you please | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in  franchise. More | Follow @TracyStaton

@EricPFierce: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. More | Follow @EricPFierce

@CarlyHFierce: EMA accepts Pfizer app to expand Prevenar in adults. FierceVaccines story | Follow @CarlyHFierce

> Sanofi enlists Emcure for cancer-drug marketing in India. Item

> Novo shoots for 2016 Tresiba launch as Q2 results come in strong. Story

> U.K. cost-effectiveness watchdog bars access to AstraZeneca's Iressa. Report

Vaccines News

> Bavarian Nordic the only bidder for Canada's smallpox vax supply. Item

> NIH: Ebola vaccine trial could begin as early as September. Report

> Affiris clears Phase I with Parkinson's vaccine candidate. Story

> U.K. and Novartis begin price negotiations on Bexsero. More

> Sanofi dengue vaccine filings could come as soon as next year's Q1, CEO says. Article

Pharma Manufacturing News

> Alvogen adds Asian manufacturing capacity in $187M Dream Pharma buyout. News

> Impax looking to use $400M cash stash for M&A. Report

> Fresenius awaiting FDA reinspection at plants in NY, India. Story

> Ebola outbreak puts spotlight on tobacco-based drug production. More

> Cubist issues third recall in 12 months after another CMO quality failing. Article